MX2021015882A - Fragmentos de unión a antígeno egfr y composiciones que los comprenden. - Google Patents

Fragmentos de unión a antígeno egfr y composiciones que los comprenden.

Info

Publication number
MX2021015882A
MX2021015882A MX2021015882A MX2021015882A MX2021015882A MX 2021015882 A MX2021015882 A MX 2021015882A MX 2021015882 A MX2021015882 A MX 2021015882A MX 2021015882 A MX2021015882 A MX 2021015882A MX 2021015882 A MX2021015882 A MX 2021015882A
Authority
MX
Mexico
Prior art keywords
compositions
binding fragments
egfr
egfr antigen
antigen
Prior art date
Application number
MX2021015882A
Other languages
English (en)
Spanish (es)
Inventor
Volker Schellenberger
Phillipp Kuhn
André Frenzel
Darragh Maccann
James Mcclory
Original Assignee
Amunix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Pharmaceuticals Inc filed Critical Amunix Pharmaceuticals Inc
Publication of MX2021015882A publication Critical patent/MX2021015882A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021015882A 2019-06-26 2020-06-25 Fragmentos de unión a antígeno egfr y composiciones que los comprenden. MX2021015882A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962866749P 2019-06-26 2019-06-26
US202063043486P 2020-06-24 2020-06-24
PCT/US2020/039682 WO2020264208A1 (en) 2019-06-26 2020-06-25 Egfr antigen binding fragments and compositions comprising same

Publications (1)

Publication Number Publication Date
MX2021015882A true MX2021015882A (es) 2022-04-18

Family

ID=74060335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015882A MX2021015882A (es) 2019-06-26 2020-06-25 Fragmentos de unión a antígeno egfr y composiciones que los comprenden.

Country Status (12)

Country Link
US (1) US20230312729A1 (https=)
EP (1) EP3990499A4 (https=)
JP (2) JP7847433B2 (https=)
KR (1) KR20220038356A (https=)
CN (1) CN114729056A (https=)
AU (1) AU2020303586A1 (https=)
CA (1) CA3143522A1 (https=)
CL (1) CL2021003435A1 (https=)
CO (1) CO2022000404A2 (https=)
IL (1) IL289100A (https=)
MX (1) MX2021015882A (https=)
WO (1) WO2020264208A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3976098A4 (en) 2019-05-31 2023-01-18 Zymeworks Inc. METHOD OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT THAT TARGETS HER2 FOR THE TREATMENT OF BILAGE DUCT CANCER
MX2023013382A (es) 2020-04-04 2024-01-30 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras.
KR20230041711A (ko) 2020-06-25 2023-03-24 아뮤닉스 파마슈티컬스, 인크. Her-2 표적화 이중특이적 조성물 및 이의 제조 및 사용 방법
US20240254241A1 (en) * 2021-05-11 2024-08-01 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
KR20250133776A (ko) 2023-02-10 2025-09-08 아뮤닉스 파마슈티컬스, 인크. 전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법
CN121949565A (zh) 2023-04-17 2026-05-01 阿穆尼克斯制药公司 靶向表皮生长因子受体的组合物及其制备和使用方法
WO2025122957A1 (en) 2023-12-08 2025-06-12 Amunix Pharmaceuticals, Inc. Protease activatable cytokines and methods for making and using the same
TW202547886A (zh) * 2024-02-02 2025-12-16 美商黛安瑟斯醫療運營公司 用於治療ｃ１ｓ介導的疾病和病症的組成物、劑量和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
RU2547595C2 (ru) * 2008-08-18 2015-04-10 Пфайзер Инк Антитела против ccr2
AU2014206217B2 (en) * 2009-02-03 2015-09-17 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
US20140155581A1 (en) * 2011-07-06 2014-06-05 Medimmune, Llc Methods For Making Multimeric Polypeptides
WO2013059524A2 (en) * 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
KR102442436B1 (ko) * 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
MY196448A (en) * 2015-10-30 2023-04-12 Genentech Inc Anti-Htra1 Antibodies and Methods of use Thereof
SG10201912565QA (en) * 2016-09-29 2020-02-27 Amgen Inc Low-viscosity antigen binding proteins and methods of making them
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
US20190336615A1 (en) * 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same

Also Published As

Publication number Publication date
AU2020303586A1 (en) 2022-01-20
WO2020264208A1 (en) 2020-12-30
CN114729056A (zh) 2022-07-08
IL289100A (en) 2022-02-01
JP2026000901A (ja) 2026-01-06
EP3990499A1 (en) 2022-05-04
CA3143522A1 (en) 2020-12-30
KR20220038356A (ko) 2022-03-28
CL2021003435A1 (es) 2022-09-02
US20230312729A1 (en) 2023-10-05
JP7847433B2 (ja) 2026-04-17
EP3990499A4 (en) 2023-07-05
JP2022538222A (ja) 2022-09-01
CO2022000404A2 (es) 2022-05-31

Similar Documents

Publication Publication Date Title
MX2021015882A (es) Fragmentos de unión a antígeno egfr y composiciones que los comprenden.
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
PH12022551298A1 (en) Antibodies specific for cd47, pd-l1, and uses thereof
MX2021015880A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos.
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
EA201690447A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
MX2015017487A (es) Anticuerpos cd3 humanizados o quimericos.
MX2018016364A (es) Anticuerpos anti-pd-l1.
PE20210652A1 (es) Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX2017001597A (es) Anticuerpos anti-pd-l1.
UY37030A (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos